Stockreport

Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Neumora Therapeutics, Inc.  (NMRA) 
PDF Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected in fourth quarter of 2024 Progressing clinical studies in MDD, bipolar depression and Alzheimer’s disea [Read more]